Home » Stocks » Autolus Therapeutics

Autolus Therapeutics PLC (AUTL)

Stock Price: $11.74 USD -0.06 (-0.51%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 613.42M
Revenue (ttm) 1.24M
Net Income (ttm) -130.11M
Shares Out 52.25M
EPS (ttm) -1.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $11.74
Previous Close $11.80
Change ($) -0.06
Change (%) -0.51%
Day's Open 11.97
Day's Range 11.30 - 12.04
Day's Volume 42,028
52-Week Range 3.00 - 17.19

More Stats

Market Cap 613.42M
Enterprise Value 428.81M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 52.25M
Float 52.17M
EPS (basic) -2.76
EPS (diluted) -1.40
FCF / Share -2.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 729,250
Short Ratio 9.84
Short % of Float 1.40%
Beta 2.02
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 495.89
PB Ratio 2.47
Revenue 1.24M
Operating Income -156.81M
Net Income -130.11M
Free Cash Flow -119.25M
Net Cash 184.61M
Net Cash / Share 3.53
Gross Margin -9,504.87%
Operating Margin -12,676.39%
Profit Margin -10,518.20%
FCF Margin -9,640.10%
ROA -22.28%
ROE -29.62%
ROIC -158.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 9
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$27.44*
(133.73% upside)
Low
13.0
Current: $11.74
High
50.0
Target: 27.44
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue2.911.411.691.21
Revenue Growth106.68%-16.89%39.69%-
Gross Profit2.911.411.691.21
Operating Income-146-57.53-23.42-14.38
Net Income-124-44.75-19.73-12.55
Shares Outstanding43.0731.5613.789.93
Earnings Per Share-2.88-1.42-1.43-1.26
Operating Cash Flow-101-31.54-16.36-9.85
Capital Expenditures-18.34-9.12-2.88-1.86
Free Cash Flow-120-40.66-19.24-11.70
Cash & Equivalents21118910228.06
Total Debt26.22--0.19
Net Cash / Debt18518910227.87
Assets30421811734.18
Liabilities48.6912.523.623.49
Book Value25520511430.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Autolus Therapeutics PLC
Country United Kingdom
Employees 290
CEO Christian Martin Itin

Stock Information

Ticker Symbol AUTL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AUTL
IPO Date June 22, 2018

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of hematological malignancies and solid tumors. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 for the treatment of multiple myeloma; AUTO4 and AUTO 5 for T cell lymphoma; and AUTO6 and AUTO7 to treat solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.